Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8848MR)

This product GTTS-WQ8848MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8848MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9353MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ4250MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ4605MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ15886MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ4980MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ5423MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ5962MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ13081MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-00547659
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW